BioCardia, Inc. (BCDA) stock

BCDANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30

$0.83−0.10 (-10.38%)

Close on Nov 12, 2026Market cap $12.50MP/E –Yield –

Earnings

BioCardia's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Nov 11, 2026

Q3 FY2026 · estimated, after the close

Revenue, Q1 FY2026

–

EPS, Q1 FY2026

-$0.21

-$0.59 a year earlier

Latest guidance

None

No outlook given in releases

Quarterly results

Revenue and earnings per share from each of BioCardia's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Source
Q3 FY2026ended Sep 30, 2026	Nov 11, 2026Expected	–	–	–	–
Q2 FY2026ended Jun 30, 2026	Aug 12, 2026after the close	–	–	–	Release
Q1 FY2026ended Mar 31, 2026	May 15, 2026before the open	–	–	-$0.21	Release
Q4 FY2025ended Dec 31, 2025	Mar 24, 2026after the close	–	–	–	Release
Q3 FY2025ended Sep 30, 2025	Nov 12, 2025after the close	–	–	-$0.24	Release
Q2 FY2025ended Jun 30, 2025	Aug 11, 2025before the open	–	–	-$0.40	Release
Q1 FY2025ended Mar 31, 2025	May 14, 2025after the close	–	–	-$0.59	Release
Q4 FY2024ended Dec 31, 2024	Mar 26, 2025after the close	–	–	–	Release
Q3 FY2024ended Sep 30, 2024	Nov 13, 2024after the close	–	–	–	Release
Q2 FY2024ended Jun 30, 2024	Aug 13, 2024after the close	$3.00K	-93.0%	-$0.88	Release
Q1 FY2024ended Mar 31, 2024	May 14, 2024after the close	$55.00K	-14.1%	-$0.09	Release
Q4 FY2023ended Dec 31, 2023	Mar 27, 2024after the close	–	–	–	Release
Q3 FY2023ended Sep 30, 2023	Nov 8, 2023after the close	$357.00K	+68.4%	-$0.12	Release
Q2 FY2023ended Jun 30, 2023	Aug 9, 2023after the close	$43.00K	-95.7%	-$0.17	Release
Q1 FY2023ended Mar 31, 2023	May 10, 2023after the close	$64.00K	+6.7%	-$0.17	Release
Q4 FY2022ended Dec 31, 2022	Mar 29, 2023before the open	–	–	–	Release
Q3 FY2022ended Sep 30, 2022	Nov 9, 2022after the close	$212.00K	-74.2%	-$0.17	Release
Q2 FY2022ended Jun 30, 2022	Aug 10, 2022after the close	$1.00M	–	-$0.14	Release
Q1 FY2022ended Mar 31, 2022	May 11, 2022after the close	$60.00K	–	-$0.19	Release
Q4 FY2021ended Dec 31, 2021	Mar 29, 2022after the close	–	–	–	Release
Q3 FY2021ended Sep 30, 2021	Nov 10, 2021after the close	$821.00K	–	-$0.16	Release
Q2 FY2021ended Jun 30, 2021	Aug 12, 2021before the open	–	–	–	Filing
Q1 FY2021ended Mar 31, 2021	May 13, 2021before the open	–	–	–	Filing
Q4 FY2020ended Dec 31, 2020	Mar 30, 2021before the open	–	–	–	Filing
Q2 FY2020ended Jun 30, 2020	Aug 13, 2020before the open	–	–	–	Filing
Q3 FY2016ended Sep 30, 2016	Nov 14, 2016after the close	–	–	–	Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

BioCardia has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When BioCardia puts a forecast in an earnings release, it is listed here with the exact sentence.